The mission of Journal of Addiction Medicine, the official peer-reviewed journal of the American Society of Addiction Medicine, is to promote excellence in the practice of addiction medicine and in clinical research as well as to support Addiction Medicine as a mainstream medical specialty.
JAM provides authors rapid publication of results via electronic published ahead-of-print and the Ovid platform, easily navigable manuscript submission software, and a steadily growing ISI Impact Factor. JAM is read by one of the largest addiction-specialty physician readerships on the globe: ASAM members as well as their professional colleagues. Additionally, JAM was accepted for citation in June 2011 by the National Library of Medicine. This development facilitates increased dissemination of content and has since been augmented with significantly expanded pagination. Since inception, JAM has been cited by peer-reviewed global search engines, including BIOSIS Previews and PsychINFO.
Published six times a year, the Journal is designed for all physicians and other mental health professionals who need to keep up-to-date with the treatment of addiction disorders. Under the guidance of an esteemed Editorial Board, peer-reviewed articles published in the Journal focus on developments in addiction medicine as well as on treatment innovations and ethical, economic, forensic, and social topics including:
- Addiction in pregnancy
- Adolescent addiction
- The drug-exposed neonate
- Neuroimaging techniques
- Treatment of special populations
- Treatment of addiction-related disorders
- Gambling addiction
- Pathophysiology of addiction
- Biological and non-biological therapies
- Issues in graduate medical education
Publication & Editorial Staff Contacts
Senior Production Editor
Translation, Rights & Licensing
LWW Business Offices
Two Commerce Square
2001 Market Street
Philadelphia, PA 19103
|Senior Editor |
Richard Saitz, MD, MPH, FASAM, FACP
Shannon C. Miller, MD, FASAM, DFAPA, CTTS
Martha J. Wunsch, MD, FAAP, FASAM
Frank J. Vocci, PhD
Christopher W. Kahler, PhD
Michael A. Arends
Richard Saitz, MD, MPH, FASAM, FACP, is a general internist and primary physician, Chair and Professor of Community Health Sciences at Boston University (BU) School of Public Health, and Professor of Medicine at BU School of Medicine. He is a Fellow of the American College of Physicians and of the American Society of Addiction Medicine, and is certified by the American Board of Internal Medicine and by the American Board of Addiction Medicine.
Shannon C. Miller, MD, FASAM, DFAPA, CTTS, is a staff psychiatrist at the Veterans Affairs Medical Center, Cincinnati where he serves in a variety of clinical roles, is Acting Director of the Addiction Division, and is Program Director of the Addiction Medicine Research Fellowship. He is also a Professor of Clinical Psychiatry at the University of Cincinnati College of Medicine where he serves as Associate Director of the Addiction Sciences Division, Director of its Education and Training Branch, and Co-Director of its Addiction Psychiatry Fellowship. He recently retired from the United States Air Force Research Lab, and was previously Chief of the Tri-Service Addiction Recovery Center in Washington DC. He is double-board certified in Psychiatry and Addiction Medicine, and holds additional certifications in Buprenorphine and Tobacco Treatment.
Martha J. Wunsch, MD, FAAP, FASAM, is the Medical Director of Addiction Medicine with Kaiser Permanente in the Greater Southern Alameda Area of Northern California. She is a founding member of the American Board of Addiction Medicine.
Frank J. Vocci, PhD, is President and Senior Research Scientist of Friends Research Institute in Baltimore, Maryland. He has previously served as Director of the National Institute on Drug Abuse’s Division of Pharmacotherapies and Medical Consequences of Drug Abuse and is President-Elect of The College on Problems of Drug Dependence. His research interests include developing medications for treating nicotine and stimulant dependence and evaluating best practices for treatment of opiate users with criminal justice involvement.